Compare Danaher Corporation (DHR) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.81. The key difference: Danaher Corporation pays a 0.77% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Danaher Corporation is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| DHR | MSTU | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $76.30 |
52-Week Low | $161.91 | $1.46 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
MSTU is trading at $1.81, down 4.23% today, with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% decline from November 2024 levels. A 10:1 reverse stock split is scheduled for August 2026, reflecting the fund's substantial challenges amid volatile market conditions.
The outlook remains highly risky given the leveraged structure's daily compounding effects and severe historical losses. While potential exists for recovery if underlying assets rebound, the fund's track record suggests continued vulnerability to market volatility. Investors should approach with extreme caution given the documented 95% annual decline and structural risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
